| Literature DB >> 34552324 |
Yuanyuan Li1, Dai Zhang1, Qing Ma1, Zongli Diao2, Sha Liu2, Xiaotian Shi1.
Abstract
PURPOSE: To explore the impact of frailty on adverse outcomes in elderly hemodialysis (HD) patients. PATIENTS AND METHODS: An observational and prospective cohort study was conducted in elderly patients (≥60) with HD, with an average 12-month follow-up. Fried frailty phenotype (FFP) was used to define frailty. Negative binomial regression was used to estimate the impact of frailty on the incidence of emergency visits, hospitalizations, acute cardiovascular events, and falls within a year. Cox regression analysis was used to assess the influence of frailty on all-cause mortality in elderly HD patients.Entities:
Keywords: elderly people; emergency visits; frailty; hemodialysis; hospitalizations; mortality
Mesh:
Year: 2021 PMID: 34552324 PMCID: PMC8450604 DOI: 10.2147/CIA.S329665
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Figure 1Prevalence of frailty in elderly hemodialysis patients according to the FFP.
Baseline Characteristics of the Included Participants by FFP
| Non-Frail (N=98) | Frail (N=52) | ||
|---|---|---|---|
| Age, median, IQR | 67.0 (64.0, 71.3) | 73.5 (68.3, 80.0) | <0.001† |
| Gender, male, n (%) | 51.0 (52.0) | 22 (42.3) | 0.304 |
| BMI, kg/m2, x±s | 23.0±3.2 | 23.3±4.8 | 0.950 |
| Smoking, n (%) | 41.0 (41.8) | 15 (28.8) | 0.156 |
| Medical history | |||
| Fall, n (%) | 30.0 (30.9) | 24 (46.2) | 0.065 |
| Fracture, n (%) | 14.0 (14.3) | 11 (21.6) | 0.259 |
| Hypertension, n (%) | 96.0 (98.0) | 51 (98.1) | 0.961 |
| DM, n (%) | 22.0 (22.4) | 23(44.2) | 0.006* |
| CHD, n (%) | 34.0 (34.7) | 27(51.9) | 0.041* |
| CPD, n (%) | 5.0 (5.1) | 4 (7.7) | 0.720 |
| Tumor, n (%) | 10.0 (10.2) | 6 (11.5) | 0.801 |
| MNA-SF, score, median, IQR | 13.0 (12.0, 14.0) | 11.0 (10.0, 12.0) | <0.001† |
| WBC, ^109/L, median, IQR | 5.9 (4.7, 4.8) | 5.9 (4.7, 7.4) | 0.506 |
| Hemoglobin, g/L, x±s | 117.1±11.6 | 115.5±15.4 | 0.372 |
| Albumin g/L, x±s | 37.5±2.7 | 35.5±2.8 | <0.001† |
| TC, mmol/L, x±s | 4.10±0.97 | 3.84±1.1 | 0.143 |
| TG, mmol/L, median, IQR | 1.5 (1.2, 2.0) | 1.2 (0.8, 2.1) | 0.065 |
| Calcium, mmol/L, median, IQR | 2.3 (2.1, 2.4) | 2.3 (2.2, 2.4) | 0.118 |
| Phosphate, mmol/L, x±s | 1.8±0.5 | 1.7±0.4 | 0.054 |
| TS, % median, IQR | 27.3 (22.9, 35.6) | 25.6 (19.7, 33.8) | 0.144 |
| PTH, mmol/L, median, IQR | 158.4(86.2, 259.8) | 203.3 (103.8, 299.0) | 0.126 |
| URR, %, median, IQR | 72.2(67.6, 75.6) | 72.2 (68.0, 76.8) | 0.810 |
Note: *p<0.05; †p<0.001.
Abbreviations: BMI, Body mass index; DM, diabetes, CHD, coronary heart disease; CPD, chronic pulmonary disease; MNA-SF, mini-nutritional assessment short form; WBC, white blood cells; TC, total cholesterol; TG, triglycerides; TS, transferrin saturation; PTH, parathyroid hormone; URR, Urea reduction rate.
Figure 2Kaplan–Meier survival curves by frailty status.
The Impact of Frailty and Its Components on Adverse Outcomes(Adjusted)
| All-Cause Mortalitya | Emergency Visitsa | Hospitalizationsa | Acute Cardiovascularb Events | Fallsc | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | IRR (95% CI) | IRR (95% CI) | IRR (95% CI) | IRR (95% CI) | ||||||
| Non-frail | Reference | Reference | Reference | Reference | Reference | |||||
| Frail | 4.10 (1.09–15.43) | 0.037* | 2.78 (1.70–4.60) | <0.001† | 1.70 (0.92–3.12) | 0.085 | 2.14 (0.67–7.07) | 0.190 | 1.28 (0.37–4.28) | 0.656 |
| Frail component | ||||||||||
| Weight loss | 3.42 (0.78–15.12) | 0.104 | 1.46 (0.73–2.93) | 0.249 | 0.89 (0.39–1.97) | 0.770 | 0.51 (0.09–2.23) | 0.359 | 0.68 (0.17–2.67) | 0.584 |
| Slow gait speed | 5.56 (1.41–22.00) | 0.014* | 2.52 (1.48–4.33) | <0.001† | 2.24 (1.19–4.21) | 0.010* | 2.09 (0.56–8.05) | 0.252 | 2.29 (0.61–8.96) | 0.157 |
| Weak grip strength | 2.80 (0.68–11.51) | 0.154 | 1.32 (0.80–2.19) | 0.271 | 1.18 (0.65–2.15) | 0.580 | 1.12 (0.33–3.73) | 0.859 | 0.98 (0.30–3.13) | 0.973 |
| Exhaustion | 1.58 (0.54–4.59) | 0.403 | 2.07 (1.34–3.23) | 0.001* | 1.57 (0.92–2.68) | 0.095 | 4.98 (1.57–18.03) | 0.005* | 1.27 (0.46–3.43) | 0.631 |
| Low physical activity | 2.92 (0.85–10.08) | 0.090 | 1.92 (1.22–3.04) | 0.004* | 1.90 (1.12–3.24) | 0.017* | 1.81 (0.58–5.80) | 0.287 | 2.26 (0.81–6.52) | 0.092 |
Notes: aAdjusted for age, gender, albumin, MNA-SF, medical history of CHD and DM, URR. bAdjusted for age, gender, albumin, medical history of DM and CHD, low-density lipoprotein cholesterol, smoking status and URR. cAdjusted for age, gender, albumin, MNA-SF and URR. *p < 0.05; †p<0.001.